CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $90 from $93 and keeps a Buy rating on the shares.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR ...

CRISPR Therapeutics (CRSP) shares closed at US$53.77 on Friday, with recent returns mixed, including a 2.5% gain over the past day but a weaker pattern over the month and the past 3 months. See our ...

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...

BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announce presentation of new data on exa-cel, ...

(Nanowerk News) The Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS) has spearheaded the development of a novel analysis service platform named CRISPRimmunity. This ...

Nearly a year after Intellia Therapeutics showed the world how its CRISPR-based therapy safely edits genes inside a patient, the biotech now has additional clinical data indicating that the ...